vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and California Resources Corp (CRC). Click either name above to swap in a different company.

California Resources Corp is the larger business by last-quarter revenue ($119.0M vs $77.6M, roughly 1.5× Bioceres Crop Solutions Corp.). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -46.3%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

California Resources Corporation is an American energy corporation engaged in hydrocarbon exploration in California. It is organized in Delaware and headquartered in Long Beach, California. Its mineral acreage holdings in California constitute the largest privately held position in the state.

BIOX vs CRC — Head-to-Head

Bigger by revenue
CRC
CRC
1.5× larger
CRC
$119.0M
$77.6M
BIOX
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-46.3%
CRC

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
CRC
CRC
Revenue
$77.6M
$119.0M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
-597.5%
Net Margin
-9.6%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$-8.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CRC
CRC
Q1 26
$119.0M
Q4 25
$679.0M
Q3 25
$77.6M
$715.0M
Q2 25
$702.0M
Q1 25
$60.6M
$814.0M
Q4 24
$98.8M
$826.0M
Q3 24
$93.3M
$870.0M
Q2 24
$412.0M
Net Profit
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
$12.0M
Q3 25
$-7.4M
$64.0M
Q2 25
$172.0M
Q1 25
$-1.6M
$115.0M
Q4 24
$605.2K
$33.0M
Q3 24
$-6.2M
$345.0M
Q2 24
$8.0M
Gross Margin
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
CRC
CRC
Q1 26
-597.5%
Q4 25
6.9%
Q3 25
9.3%
13.7%
Q2 25
38.0%
Q1 25
1.5%
22.9%
Q4 24
14.5%
8.2%
Q3 24
2.5%
59.5%
Q2 24
9.2%
Net Margin
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
1.8%
Q3 25
-9.6%
9.0%
Q2 25
24.5%
Q1 25
-2.6%
14.1%
Q4 24
0.6%
4.0%
Q3 24
-6.6%
39.7%
Q2 24
1.9%
EPS (diluted)
BIOX
BIOX
CRC
CRC
Q1 26
$-8.02
Q4 25
$0.21
Q3 25
$-0.12
$0.76
Q2 25
$1.92
Q1 25
$-0.02
$1.26
Q4 24
$0.00
$0.87
Q3 24
$-0.10
$3.78
Q2 24
$0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CRC
CRC
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$2.9B
Total Assets
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
$132.0M
Q3 25
$15.5M
$196.0M
Q2 25
$72.0M
Q1 25
$38.5M
$214.0M
Q4 24
$29.2M
$372.0M
Q3 24
$32.3M
$241.0M
Q2 24
$1.0B
Total Debt
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
Q3 25
$1.0B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.2B
Stockholders' Equity
BIOX
BIOX
CRC
CRC
Q1 26
$2.9B
Q4 25
$3.7B
Q3 25
$288.3M
$3.4B
Q2 25
$3.4B
Q1 25
$345.0M
$3.5B
Q4 24
$346.3M
$3.5B
Q3 24
$346.0M
$3.5B
Q2 24
$2.1B
Total Assets
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
$7.4B
Q3 25
$734.9M
$6.8B
Q2 25
$6.7B
Q1 25
$798.2M
$6.8B
Q4 24
$835.2M
$7.1B
Q3 24
$827.3M
$7.1B
Q2 24
$4.5B
Debt / Equity
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
Q3 25
0.29×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.32×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CRC
CRC
Operating Cash FlowLast quarter
$14.4M
$99.0M
Free Cash FlowOCF − Capex
$-32.0M
FCF MarginFCF / Revenue
-26.9%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$380.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CRC
CRC
Q1 26
$99.0M
Q4 25
$235.0M
Q3 25
$14.4M
$279.0M
Q2 25
$165.0M
Q1 25
$23.3M
$186.0M
Q4 24
$-5.4M
$206.0M
Q3 24
$5.2M
$220.0M
Q2 24
$97.0M
Free Cash Flow
BIOX
BIOX
CRC
CRC
Q1 26
$-32.0M
Q4 25
$115.0M
Q3 25
$188.0M
Q2 25
$109.0M
Q1 25
$131.0M
Q4 24
$118.0M
Q3 24
$141.0M
Q2 24
$63.0M
FCF Margin
BIOX
BIOX
CRC
CRC
Q1 26
-26.9%
Q4 25
16.9%
Q3 25
26.3%
Q2 25
15.5%
Q1 25
16.1%
Q4 24
14.3%
Q3 24
16.2%
Q2 24
15.3%
Capex Intensity
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
17.7%
Q3 25
12.7%
Q2 25
8.0%
Q1 25
6.8%
Q4 24
10.7%
Q3 24
9.1%
Q2 24
8.3%
Cash Conversion
BIOX
BIOX
CRC
CRC
Q1 26
Q4 25
19.58×
Q3 25
4.36×
Q2 25
0.96×
Q1 25
1.62×
Q4 24
-8.85×
6.24×
Q3 24
0.64×
Q2 24
12.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons